Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management
Listen to expert hematologists provide an up-to-date clinical overview of paroxysmal nocturnal hemoglobinuria (PNH), exploring its pathogenesis, clinical manifestations, and the evolution of complement-based therapies.
Decera Clinical Education Oncology Podcast · Carlos M. De Castro MD, David Dingli MD PhD FRCP FRCPEd FACP FRCPath
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes and quality of life. The conversation blends clinical insights with practical considerations for therapy selection and patient care, including:
- The pathogenesis of PNH and the role of complement activation
- Landmark therapies such as eculizumab and ravulizumab
- Advances in proximal inhibitors (eg, pegcetacoplan, iptacopan, danicopan)
- Quality-of-life considerations, treatment personalization, and emerging therapies
Presenters:
Carlos M. De Castro, MD
Professor of Medicine, DUMC
Division of Malignant Hematology and Cellular Therapy
Department of Medicine
Duke University
Duke Cancer Institute
Durham, North Carolina
David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath
Consultant Hematologist and Director of Bone Marrow Transplant Program
Professor of Medicine
Division of Hematology
Mayo Clinic College of Medicine and Science
Rochester, Minnesota
Link to full program:
https://bit.ly/3Jtjqgr
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.